Compare, Analyse Elder Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ELDER PHARMA   ACTAVIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ACTAVIS
Dec-18
ELDER PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs38014,220-   
Low Rs1889,539-   
Sales per share (Unadj.) Rs491.23,488.2-  
Earnings per share (Unadj.) Rs-3.2-1,123.6-  
Cash flow per share (Unadj.) Rs14.4367.6-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.514,387.3-  
Shares outstanding (eoy) m20.54332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.4 17.0%   
Avg P/E ratio x-89.3-10.6 844.2%  
P/CF ratio (eoy) x19.732.3 61.0%  
Price / Book Value ratio x0.80.8 91.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8333,951,174 0.1%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m2,1790-   
Avg. sales/employee Rs ThNM68,650.1-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-22,112.2-  
INCOME DATA
Net Sales Rs m10,0891,160,187 0.9%  
Other income Rs m25722,187 1.2%   
Total revenues Rs m10,3461,182,373 0.9%   
Gross profit Rs m-79230,403 -2.6%  
Depreciation Rs m361495,955 0.1%   
Interest Rs m2,75666,949 4.1%   
Profit before tax Rs m-3,653-510,315 0.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713130,151 2.9%   
Tax Rs m125-6,467 -1.9%   
Profit after tax Rs m-65-373,697 0.0%  
Gross profit margin %-7.82.6 -299.5%  
Effective tax rate %-3.41.3 -270.3%   
Net profit margin %-0.6-32.2 2.0%  
BALANCE SHEET DATA
Current assets Rs m9,240475,848 1.9%   
Current liabilities Rs m9,998420,951 2.4%   
Net working cap to sales %-7.54.7 -158.7%  
Current ratio x0.91.1 81.8%  
Inventory Days Days4620 236.5%  
Debtors Days Days6066 90.4%  
Net fixed assets Rs m10,124131,327 7.7%   
Share capital Rs m2060-   
"Free" reserves Rs m5,5820-   
Net worth Rs m7,7344,785,228 0.2%   
Long term debt Rs m4,8891,685,052 0.3%   
Total assets Rs m22,8827,480,400 0.3%  
Interest coverage x-0.3-6.6 4.9%   
Debt to equity ratio x0.60.4 179.5%  
Sales to assets ratio x0.40.2 284.3%   
Return on assets %11.8-4.1 -286.8%  
Return on equity %-0.8-7.8 10.8%  
Return on capital %22.3-4.8 -460.9%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Net fx Rs m1810-   
CASH FLOW
From Operations Rs m11,754414,491 2.8%  
From Investments Rs m-561227,709 -0.2%  
From Financial Activity Rs m-6,762-711,391 1.0%  
Net Cashflow Rs m4,432-68,845 -6.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.49 Rs / USD

Compare ELDER PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ELDER PHARMA With: JUBILANT PHARMOVA   DIVIS LABORATORIES  ALEMBIC PHARMA  GSK PHARMA  NOVARTIS  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views On News

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market (Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution (Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ELDER PHARMA

ELDER PHARMA - J.B.CHEMICALS COMPARISON

COMPARE ELDER PHARMA WITH

FEATURED VIDEOS

Top Pick for Next Decade

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

More Featured Videos

MARKET STATS